REFERENCES
1. Ali Y, Abd Hamid S. Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy. Tumor Biol 2016;37:47-55.
2. Mondal N, Parvin JD. DNA topoisomerase IIalpha is required for RNA polymerase II transcription on chromatin templates. Nature 2001;413:435-8.
3. Akimitsu N, Adachi N, Hirai H, Hossain MS, Hamamoto H, et al. Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase II alpha. Genes Cells 2003;8:393-402.
4. Collins I, Weber A, Levens D. Transcriptional consequences of topoisomerase inhibition. Mol Cell Biol 2001;21:8437-51.
5. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413.
6. Clarke DJ, Azuma Y. Non-catalytic roles of the topoisomerase II C-terminal domain. Int J Mol Sci 2017;18.
8. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase-Ii by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci U S A 1994;91:1781-5.
9. Wu CC, Li TK, Farh L, Lin LY, Lin TS, et al. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science 2011;333:459-62.
10. Vassetzky YS, Alghisi GC, Gasser SM. DNA topoisomerase II mutations and resistance to anti-tumor drugs. Bioessays 1995;17:767-74.
12. Han ZJ, Feng YH, Gu BH, Li YM, Chen H. The post-translational modification, SUMOylation, and cancer (review). Int J Oncol 2018;52:1081-94.
13. Saijo M, Enomoto T, Hanaoka F, Ui M. Purification and characterization of type II DNA topoisomerase from mouse Fm3a cells: phosphorylation of topoisomerase-Ii and modification of its activity. Biochemistry 1990;29:583-90.
14. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol 2003;21:255-61.
15. Chen T, Sun Y, Ji P, Kopetz S, Zhang W. Topoisomerase IIalpha in chromosome instability and personalized cancer therapy. Oncogene 2015;34:4019-31.
16. Bedez C, Lotz C, Batisse C, Broeck AV, Stote RH, et al. Post-translational modifications in DNA topoisomerase 2α highlight the role of a eukaryote-specific residue in the ATPase domain. Sci Rep 2018;8:9272.
17. Wells NJ, Fry AM, Guano F, Norbury C, Hickson ID. Cell cycle phase-specific phosphorylation of human topoisomerase II alpha. Evidence of a role for protein kinase C. J Biol Chem 1995;270:28357-63.
18. Grozav AG, Chikamori K, Grabowski DR, Xu Y, Kinter M, et al. Casein kinase I delta/epsilon isoforms phosphorylate serine 1106 in the catalytic domain of human topoisomerase II alpha. Cancer Res 2006;47.
19. Shapiro PS, Whalen AM, Tolwinski NS, Wilsbacher J, Froelich-Ammon SJ, et al. Extracellular signal-regulated kinase activates topoisomerase II alpha through a mechanism independent of phosphorylation. Mol Cell Biol 1999;19:3551-60.
20. Adachi N, Miyaike M, Kato S, Kanamaru R, Koyama H, et al. Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain. Nucleic Acids Res 1997;25:3135-42.
21. Ishida R, Takashima R, Koujin T, Shibata M, Nozaki N, et al. Mitotic specific phosphorylation of serine-1212 in human DNA topoisomerase II alpha. Cell Struct Funct 2001;26:215-26.
22. Devore RF, Corbett AH, Osheroff N. Phosphorylation of topoisomerase II by casein kinase II and protein kinase c: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4’-(9-Acridinylamino) methane-sulfon-m-anisidide. Cancer Res 1992;52:2156-61.
23. Plo I, Hernandez H, Kohlhagen G, Lautier D, Pommier Y, et al. Overexpression of the atypical protein kinase C reduces topoisomerase II catalytic activity, cleavable complexes formation, and drug-induced cytotoxicity in monocytic U937 leukemia cells. J Biol Chem 2002;277:31407-15.
24. Chikamori K, Grabowski DR, Kinter M, Willard BB, Yadav S, et al. Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity. J Biol Chem 2003;278:12696-702.
25. Shiozaki K, Yanagida M. Functional dissection of the phosphorylated termini of fission yeast DNA topoisomerase-II. J Cell Biol 1992;119:1023-36.
26. Luo KT, Yuan J, Chen JJ, Lou ZK. Topoisomerase IIalpha controls the decatenation checkpoint. Nat Cell Biol 2009;11:204-10.
27. Wells NJ, Addison CM, Fry AM, Ganapathi R, Hickson ID. Serine 1524 is a major site of phosphorylation on human topoisomerase II alpha protein in vivo and is a substrate for casein kinase II in vitro. J Biol Chem 1994;269:29746-51.
28. Li H, Wang Y, Liu X. Plk1-dependent phosphorylation regulates functions of DNA topoisomerase II alpha in cell cycle progression. J Biol Chem 2008;283:6209-21.
29. Qi XM, Hou SW, Lepp A, Li RS, Basir Z, et al. Phosphorylation and stabilization of topoisomerase II alpha protein by p38 gamma mitogen-activated protein kinase sensitize breast cancer cells to its poisons. J Biol Chem 2011;286:35883-90.
30. Lane AB, Gimenez-Abian JF, Clarke DJ. A novel chromatin tether domain controls topoisomerase II alpha dynamics and mitotic chromosome formation. J Cell Biol 2013;203:471-86.
31. Corbett AH, Fernald AW, Osheroff N. Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of atp hydrolysis: evidence for a common mechanism of regulation by phosphorylation. Biochemistry 1993;32:2090-7.
32. Corbett AH, Devore RF, Osheroff N. Effect of casein kinase-II-mediated phosphorylation on the catalytic cycle of topoisomerase II. Regulation of enzyme activity by enhancement of ATP hydrolysis. J Biol Chem 1992;267:20513-8.
33. Takano H, Kohno K, Ono M, Uchida Y, Kuwano M. Increased phosphorylation of DNA topoisomerase-II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 1991;51:3951-7.
34. Nakazawa N, Arakawa O, Ebe M, Yanagida M. Casein kinase II-dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast. J Biol Chem 2019;294:3772-82.
35. Matsumoto Y, Takano H, Fojo T. Cellular adaptation to drug exposure: Evolution of the drug-resistant phenotype. Cancer Res 1997;57:5086-92.
36. Ritke MK, Allan WP, Fattman C, Gunduz NN, Yalowich JC. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Mol Pharmacol 1994;46:58-66.
37. Ganapathi R, Constantinou A, Kamath N, Dubyak G, Grabowski D, et al. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. Mol Pharmacol 1996;50:243-48.
38. Choudhary C, Weinert BT, Nishida Y, Verdin E, Mann M. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat Rev Mol Cell Biol 2014;15:536-50.
39. Mertins P, Qiao JW, Patel J, Udeshi ND, Clauser KR, et al. Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 2013;10:634-7.
40. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res 2015;43:D512-20.
41. Wu Q, Cheng ZY, Zhu J, Xu WQ, Peng XJ, et al. Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 2015;5:9520.
42. Udeshi ND, Svinkina T, Mertins P, Kuhn E, Mani DR, et al. Refined preparation and use of anti-diglycine remnant (K-epsilon-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 2013;12:825-31.
43. Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 2011;44:325-40.
44. Povlsen LK, Beli P, Wagner SA, Poulsen SL, Sylvestersen KB, et al. Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol 2012;14:1089-98.
45. Wagner SA, Beli P, Weinert BT, Nielsen ML, Cox J, et al. A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol Cell Proteomics 2011;10:M111.013284.
46. Akimov V, Barrio-Hernandez I, Hansen SVF, Hallenborg P, Pedersen AK, et al. UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 2018;25:631-40.
47. Hendriks IA, D’Souza RCJ, Yang B, Verlaan-de Vries M, Mann M, et al. Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Molr Biol 2014;21:927-36.
48. Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D, et al. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 2000;26:349-53.
49. Johnson CA, Padget K, Austin CA, Turner BM. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J Biol Chem 2001;276:4539-42.
50. Chen MC, Chen CH, Chuang HC, Kulp SK, Teng CM, et al. Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase II alpha degradation in hepatocellular carcinoma cells. Hepatology 2011;53:148-59.
51. Gilberto S, Peter M. Dynamic ubiquitin signaling in cell cycle regulation. J Cell Biol 2017;216:2259-71.
52. Eguren M, Alvarez-Fernandez M, Garcia F, Lopez-Contreras AJ, Fujimitsu K, et al. A synthetic lethal interaction between APC/C and topoisomerase poisons uncovered by proteomic screens. Cell Rep 2014;6:670-83.
53. Guturi KKN, Bohgaki M, Bohgaki T, Srikumar T, Ng D, et al. RNF168 and USP10 regulate topoisomerase II alpha function via opposing effects on its ubiquitylation. Nat Commun 2016;7:12638.
54. Kang X, Song C, Du X, Zhang C, Liu Y, et al. PTEN stabilizes TOP2A and regulates the DNA decatenation. Sci Rep 2015;5:17873.
55. Fielding AB, Concannon M, Darling S, Rusilowicz-Jones EV, Sacco JJ, et al. The deubiquitylase USP15 regulates topoisomerase II alpha to maintain genome integrity. Oncogene 2018;37:2326-42.
56. Senturk JC, Bohlman S, Manfredi JJ. Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53. Oncogene 2017;36:6085-96.
57. Ogiso Y, Tomida A, Lei SH, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 2000;60:2429-34.
58. Alchanati I, Teicher C, Cohen G, Shemesh V, Barr HM, et al. The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2 alpha cleavage complex - a potentially new drug target. PloS One 2009;4:e8104.
59. Sun Y, Miller Jenkins LM, Su YP, Nitiss KC, Nitiss JL, et al. A conserved SUMO-Ubiquitin pathway directed by RNF4/SLX5-SLX8 and PIAS4/SIZI drives proteasomal degradation of topoisomerase DNA-protein crosslinks. Bio Rxiv 2019. Available from: https://www.biorxiv.org/content/10.1101/707661v1 [Last accessed on 20 Feb 2020].
61. Schellenberg MJ, Lieberman JA, Herrero-Ruiz A, Butler LR, Williams JG, et al. ZATT (ZNF451)-mediated resolution of topoisomerase 2 DNA-protein cross-links. Science 2017;357:1412-6.
62. Dawlaty MM, Malureanu L, Jeganathan KB, Kao E, Sustmann C, et al. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase II alpha. Cell 2008;133:103-15.
63. Ryu H, Furuta M, Kirkpatrick D, Gygi SP, Azuma Y. PIASy-dependent SUMOylation regulates DNA topoisomerase II alpha activity. J Cell Biol 2010;191:783-94.
64. Antoniou-Kourounioti M, Mimmack ML, Porter ACG, Farr CJ. The impact of the C-terminal region on the interaction of topoisomerase II alpha with mitotic chromatin. Int J Mol Sci 2019;20.
65. Edgerton H, Johansson M, Keifenheim D, Mukherjee S, Chacon JM, et al. A noncatalytic function of the topoisomerase II CTD in Aurora B recruitment to inner centromeres during mitosis. J Cell Biol 2016;213:651-64.
66. Chen SF, Huang NL, Lin JH, Wu CC, Wang YR, et al. Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate. Nat Commun 2018;9:3085.
67. Vanden Broeck A, Lotz C, Ortiz J, Lamour V. Cryo-EM structure of the complete E. coli DNA gyrase nucleoprotein complex. Nat Commun 2019;10:4935.
68. Petrella S, Capton E, Raynal B, Giffard C, Thureau A, et al. Overall structures of mycobacterium tuberculosis DNA gyrase reveal the role of a corynebacteriales GyrB-specific insert in ATPase activity. Structure 2019;27:579-89.e5.
69. Wendorff TJ, Schmidt BH, Heslop P, Austin CA, Berger JM. The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol 2012;424:109-24.
70. Agostinho M, Santos V, Ferreira F, Costa R, Cardoso J, et al. Conjugation of human topoisomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity. Cancer Res 2008;68:2409-18.
71. Mao Y, Desai SD, Liu LF. SUMO-1 conjugation to human DNA topoisomerase II isozymes. J Biol Chem 2000;275:26066-73.
72. Blower TR, Bandak A, Lee ASY, Austin CA, Nitiss JL, et al. A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents. Nucleic Acids Res 2019;47:8163-79.
73. Wessel I, Jensen LH, Renodon-Corniere A, Sorensen TK, Nitiss JL, et al. Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the walker A ATP binding site of topoisomerase II alpha. FEBS Lett 2002;520:161-6.
74. Renodon-Corniere A, Jensen LH, Nitiss JL, Jensen PB, Sehested M. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance. Biochemistry 2003;42:9749-54.
75. Jensen LH, Wessel I, Moller M, Nitiss JL, Sehested M, et al. N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance. FEBS Lett 2000;480:201-7.
76. Miller ML, Ponten TS, Petersen TN, Blom N. NetPhosK - Prediction of kinase-specific phosphorylation from sequence and sequence-derived features. Febs J 2005;272:111.
